Cancer risk associated with alpha-1-antitrypsin deficiency: only large registries will give us the answer
- PMID: 36302522
- DOI: 10.1183/13993003.01289-2022
Cancer risk associated with alpha-1-antitrypsin deficiency: only large registries will give us the answer
Conflict of interest statement
Conflict of interest: M. Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Kamada, Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Inhibrx, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, Spin Therapeutics, ONO Pharma, pH Pharma, Palobiofarma SL, Takeda, Novartis, Sanofi and Grifols, and research grants from Grifols. M. Barrecheguren has received speaker fees from Grifols, Menarini, CSL Behring, GSK and Boehringer Ingelheim, and consulting fees from GSK, Novartis, CSL Behring and Boehringer Ingelheim.
Comment on
-
Cancer risk in severe alpha-1-antitrypsin deficiency.Eur Respir J. 2022 Oct 27;60(4):2103200. doi: 10.1183/13993003.03200-2021. Print 2022 Oct. Eur Respir J. 2022. PMID: 35361631
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical